These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12186373)

  • 1. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
    Tham YL; Verani MS; Chang J
    Breast Cancer Res Treat; 2002 Jul; 74(2):131-4. PubMed ID: 12186373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-induced cardiomyopathy.
    Guglin M; Cutro R; Mishkin JD
    J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and clinical overview of trastuzumab (herceptin).
    Frankel C
    Semin Oncol Nurs; 2000 Nov; 16(4 Suppl 1):13-7. PubMed ID: 11151453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB; Zielinski CC
    Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
    Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
    Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
    Wadhwa D; Fallah-Rad N; Grenier D; Krahn M; Fang T; Ahmadie R; Walker JR; Lister D; Arora RC; Barac I; Morris A; Jassal DS
    Breast Cancer Res Treat; 2009 Sep; 117(2):357-64. PubMed ID: 19082707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of trastuzumab in breast cancer.
    Tokuda Y; Ohta M; Suzuki Y; Kubota M; Tajima T
    Breast Cancer; 2001; 8(2):93-7. PubMed ID: 11342980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical aspects of trastuzumab treatment in breast cancer].
    Grell P; Svoboda M; Fabián P; Petráková K; Vyzula R
    Klin Onkol; 2009; 22(1):3-10. PubMed ID: 19534433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.
    Fallah-Rad N; Lytwyn M; Fang T; Kirkpatrick I; Jassal DS
    J Cardiovasc Magn Reson; 2008 Jan; 10(1):5. PubMed ID: 18272009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review.
    Tu CM; Chu KM; Yang SP; Cheng SM; Wang WB
    Am J Emerg Med; 2009 Sep; 27(7):903.e1-3. PubMed ID: 19683138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac dysfunction in the trastuzumab clinical trials experience.
    Seidman A; Hudis C; Pierri MK; Shak S; Paton V; Ashby M; Murphy M; Stewart SJ; Keefe D
    J Clin Oncol; 2002 Mar; 20(5):1215-21. PubMed ID: 11870163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
    Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
    Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications for Herceptin in breast cancer treatment].
    Beuzeboc P
    Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.